Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review
Open Access
- 12 February 2021
- journal article
- case report
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (2) , 18
Abstract
Background: Although remdesivir treatment is widely used during the pandemic coronavirus disease 2019 (COVID-19), there is scarce evidence regarding its cardiac side effects. Case presentation: We report the case of a 36-year-old male hospitalized due to severe COVID-19 symptoms. He presented with a 10-day history of fever (up to 39.7 °C), productive cough, hemoptysis, fatigue, myalgias and hypoxemia. The patient received supplemental oxygen, dexamethasone, remdesivir and empirical antibiotic treatment according to protocol. Asymptomatic sinus bradycardia developed on hospital day 3 (namely, heart rate 39/min compared to 92/min on admission). Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. The patient’s rhythm restored to normal 9 days after the discontinuation of remdesivir. Conclusions: Considering the frequent use of remdesivir in patients with COVID-19, physicians should be aware of this possible adverse event.Keywords
This publication has 10 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Marked Sinus Bradycardia Associated With Remdesivir in COVID-19JACC: Case Reports, 2020
- Cardiac Adverse Events With Remdesivir in COVID-19 InfectionCureus, 2020
- Safety profile of the antiviral drug remdesivir: An updateBiomedicine & Pharmacotherapy, 2020
- Arrhythmias and COVID-19JACC: Clinical Electrophysiology, 2020
- Potential Effects of Coronaviruses on the Cardiovascular SystemJAMA Cardiology, 2020
- Bradycardia in Patients With COVID-19: A Calm Before the Storm?Cureus, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJournal of Biological Chemistry, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020